Investigate if Metoprolol and Troxerutin Could Prevent Cardiotoxicity Mitigated by Doxorubicin

Doxorubicin, which is widely used as an anti-tumour drug, it associated with Cardiotoxic problems. Previous studies suggested that each of the metoprolol and troxerutin alone could provide potential protection against this cardiotoxic effect. This study was aimed to investigate if the combination of these two drugs could provide superior protection against the cardiotoxic effect of doxorubicin. Fifty male Wistar rats were divided into five groups; each group had 10 animals. Both control negative and control positive groups, a treatment group for each drug and a combination group. The blood samples were collected from the animals to extract the serum, and the serums were used in Elisa technique for investigation the concentration of CK-MB, SOD, MDA, IL-6 and TNF-Alpha for all groups to study the effect of the drugs to these markers. The combination treatment group provided a superior effect in almost all groups, The combination treatment group achieved nearly the levels of the control negative group in 2 markers, which were CK-MB and TNF. In oxidative stress markers (MDA) and antioxidant (SOD), it had the lowest concentration of MDA compared to positive group. While highest concentration of antioxidant (SOD) compared to positive group suggesting a slightly better effect of the combination. In conclusion, Combination therapy provides a superior effect on key markers, suggesting its benefits by working on various pathways to protect the heart. Although the effect of the combination was still comparable in oxidative stress markers to other treatment groups, the combination therapy totally outperformed monotherapies.